Literature DB >> 7957370

Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine.

S Van Gool1, P Brock, P Van Laer, R Van Damme-Lombaerts, W Proesmans, M Casteels-Van Daele.   

Abstract

An adolescent girl with severe thrombotic thrombocytopenic purpura (TTP) remained in a critical condition after 3 weeks of combined treatment with antiplatelet drugs, plasma infusions and plasma exchange. The introduction of vincristine resulted in gradual improvement and eventual complete remission which lasted for 2 years. When she relapsed, immediate improvement was observed with the combined treatment of plasmapheresis and vincristine. She has now been in complete remission again for 10 months. It is suggested that plasmapheresis plus vincristine should be used as the initial treatment for children with TTP.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7957370     DOI： 10.1007/BF01957008

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  21 in total

1.  Letter: Vincristine therapy of thrombocytopenias.

Authors: 
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

2.  Vincristine for thrombocytopenic purpura.

Authors:  J L Welborn; R O'Donnell; T Hsieh; J Eatherton; K Aspry
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

3.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

Review 4.  HUS and TTP: variable expression of a single entity.

Authors:  G Remuzzi
Journal:  Kidney Int       Date:  1987-08       Impact factor: 10.612

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study.

Authors:  R Van Damme-Lombaerts; W Proesmans; B Van Damme; R Eeckels; P Binda ki Muaka; V Mercieca; R Vlietinck; J Vermylen
Journal:  J Pediatr       Date:  1988-11       Impact factor: 4.406

Review 7.  Thrombotic thrombocytopenic purpura.

Authors:  W G Murphy; J C Moore; T E Warkentin; C P Hayward; J G Kelton
Journal:  Blood Coagul Fibrinolysis       Date:  1992-10       Impact factor: 1.276

8.  Case report: high-dose intravenous immunoglobulin as therapy for thrombotic thrombocytopenic purpura.

Authors:  M Kolodziej
Journal:  Am J Med Sci       Date:  1993-02       Impact factor: 2.378

9.  Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group.

Authors:  G Rock; K Shumak; J Kelton; V S Blanchette; N Buskard; R Nair; R Spasoff
Journal:  Transfusion       Date:  1992-10       Impact factor: 3.157

10.  Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.

Authors:  G Finazzi; P Bellavita; A Falanga; P Viero; T Barbui
Journal:  Am J Hematol       Date:  1992-11       Impact factor: 10.047
View more
  3 in total

1.  Familial relapsing thrombotic micro-angiopathy in two siblings.

Authors:  A Hazani; A Eldor; Y Shechter; A Etzioni
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

2.  Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.

Authors:  Gideon Y Stein; Aliza Zeidman; Zinaida Fradin; Meir Varon; Amos Cohen; Moshe Mittelman
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

3.  Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Authors:  Seniz Öngören; Ayşe Salihoğlu; Tuğçe Apaydın; Sevil Sadri; Ahmet Emre Eşkazan; Muhlis Cem Ar; Tuğrul Elverdi; Zafer Başlar; Yıldız Aydın; Teoman Soysal
Journal:  Balkan Med J       Date:  2018-07-03       Impact factor: 2.021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.